Cystic Fibrosis Global Clinical Trials Review, H2, 2017

  • ID: 4376016
  • Clinical Trials
  • Region: Global
  • 467 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Nivalis Therapeutics Inc
  • MORE
Cystic Fibrosis Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Cystic Fibrosis Global Clinical Trials Review, H2, 2017" provides an overview of Cystic Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cystic Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Nivalis Therapeutics Inc
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Cystic Fibrosis Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Cystic Fibrosis
Jul 12, 2017: Synspiras Novel Glycopolymer Improves Effectiveness of Antibiotics Against Drug-resistant Bacteria Associated with Cystic Fibrosis
Jul 10, 2017: Anthera Pharmaceuticals Announces Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network
Jun 29, 2017: Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis
Jun 20, 2017: Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference
Jun 13, 2017: Pharmaxis Announces Results of Pivotal Bronchitol Cystic Fibrosis Clinical Trial for US Market
Jun 09, 2017: Vertex Announces Nine Presentations of Data on ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor) at the European Cystic Fibrosis Society Conference
Jun 08, 2017: Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
Jun 08, 2017: Corbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference
Jun 08, 2017: ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
Jun 07, 2017: Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference
Jun 07, 2017: Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs
Jun 07, 2017: Proteostasis Therapeutics Announces Update on Phase 1 Trial of PTI-808, CFTR potentiator
Jun 07, 2017: Proteostasis Therapeutics Announces Clinical Development Update on Cystic Fibrosis Drug Candidate PTI-801
Jun 05, 2017: Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDA
Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis
May 24, 2017: Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference
May 23, 2017: Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
May 17, 2017: Celtaxsys Announces Full Enrollment of Its Landmark EMPIRE-CF Phase 2b Clinical Trial Assessing the Potential of Novel Anti-inflammatory Investigational Therapy, Oral Acebilustat, to Preserve Lung Function in CF Patients
May 16, 2017: Spyryx Biosciences to Present at American Thoracic Society International Conference May 19- 24, 2017, Washington, DC
Apr 19, 2017: Laurent Pharmaceuticals Receives FDA and Health Canada Clearance to Initiate APPLAUD Phase 2 Clinical Study of LAU-7b for the Treatment of Cystic Fibrosis
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Source

List of Tables
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Region, 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
Proportion of Cystic Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2017*
Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Cystic Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2017*
Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Cystic Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Cystic Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
Proportion of Cystic Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2017*
Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Cystic Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2017*
Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Cystic Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Cystic Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Methodology
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Cystic Fibrosis Foundation
  • Vertex Pharmaceuticals Inc
  • Novartis AG
  • Gilead Sciences Inc
  • Galapagos NV
  • Allergan Plc
  • F. Hoffmann-La Roche Ltd
  • C. H. Boehringer Sohn AG & Co KG
  • Merck & Co Inc
  • Nivalis Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll